Venture Houston 2018
Skip Content

2 July 2018

I-Mab imports $220m in series C round

Tasly Pharmaceuticals contributed to a series C round for the immunotherapy developer, a year after backing its $150m series B.

Author: Robert Lavine, News Editor

China-based immunotherapy developer I-Mab Biopharma closed a $220m series C round on Friday that included Tasly Capital, the corporate venture capital subsidiary of pharmaceutical company Tasly Pharmaceuticals.